News for 'Novo Nordisk'

TCS bags Novo Nordisk deal

Abbott Bets On Semaglutide Boom

Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.

Drugmakers look to fill Rs 600 cr Novo vacuum

Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of the human insulin pen market by the end of this year and creates an opportunity estimated to be worth Rs 600-800 crore in the domestic market. Some self-use disposable pens are pre-filled with insulin and others can be reused with new cartridges.

Emcure sets sights on pan-Indian obesity market with Poviztra

Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.

Ozempic launched in India, priced at Rs 2,200 per week

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits.

Biocon launches diabetes & obesity drugs in Netherlands

Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.

'14+ Anti-Obesity Drugs In The Pipeline'

The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.

Weightloss Drugs Hit 1,000 Crore Mark

'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'

Novo, Dr Reddy's tie up for anti-diabetes pill

Indian Pharma Majors Ready With Weight Loss Drugs

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

Serena Williams shocks fans with 31-pound makeover

The 23-time Grand Slam champion, who retired from professional tennis in 2022, will headline a multi-year national marketing campaign for GLP-1 drugs, a company spokesperson said.

Diabetes Drug Linked To Vision Loss?

Study suggested that constant use of Semaglutide may be linked to development of a condition called non-arteritic ischemic optic neuropathy.

Weight-Loss Drug Battle Intensifies

'Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five times what it was five years ago.'

Wockhardt exits US generics biz, to focus on innovation

Mumbai-based pharma major Wockhardt, which is gearing up to launch its promising antibiotic candidate Zaynich soon, on Friday announced a shift in its United States (US) operations. The Indian pharma giant revealed that it has decided to exit the generics pharmaceutical segment in the country.

Mankind Pharma Targets Anti-Obesity Drug

'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'

Insulin makers cut prices

Leading insulin makers on Friday slashed the rates of human insulin by about 40 per cent, a move which will provide a big relief to diabetic patients.

1 insulin price cap for all brands

Another cap for imported insulin; domestic manufacturers cry foul.

'Jobs Have Evolved, Skill Sets Haven't'

'India has a skill shortage of 56%.' 'This is a very interesting paradox -- the unemployment rate is 6% to 7%, and at the same time 20% of those qualified are unemployed.'

'Tariffs will hurt insurance, patients and everyone'

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.

Ajay Banga, only Indian among world's best performing CEOs

Jeff Bezos tops Harvard Business Review list on financial parameters but stands 87th overall.

World's 10 best performing CEOs

Amazon CEO Jeff Bezos has been ranked as the world's best performing CEO.

Factors that will sustain Abbott outperformance

Abbott India outperformed the Indian pharmaceutical market (IPM) with a year-on-year (YoY) growth of 23 per cent in February. The domestic market grew at a robust 20 per cent on a low base, primarily led by volume growth and price hikes. Abbott continued to outperform the sector in the anti-diabetic space with a growth of 20 per cent and key brands such as Thyronorm (hypothyroidism), biliary agent Udiliv, insulin Ryzodeg posted robust growth.

'The formulations business been a growth driver'

'However, we have seen weakness in our active pharmaceutical ingredients business.'

Consumers may have to pay more for insulin

Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.

US FDA tightens regulatory noose on Indian drug firms

Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter